OncoBEAM blood test arrives to Europe

22/04/2015 - 2 minutes

Sysmex Inostics have signed an exclusive distributor agreement with IndivuTest, and its parent company Indivumed, a cancer research company focused on the development of individualized cancer diagnostics and therapies. This collaboration will offer Sysmex’s OncoBEAM services throughout Germany, Austria and Switzerland.

IndivuTest will be responsible for commercial and sample logistics, with all testing being performed in the Sysmex Inostics’ CLIA laboratory in Baltimore, Maryland.

Sysmex Inostics’ highly sensitive OncoBEAM services allow for molecular genetic analysis of cell-free tumor DNA from blood or plasma, delivering an individualized approach to complement treatment decision-making in oncology. OncoBEAM, a non-invasive platform, reveals new possibilities for cancer management, while minimizing costs and risks inherent with tissue biopsies. The OncoBEAM assays target a wide variety of clinically actionable genetic mutations in various cancers like melanoma, colorectal, breast and lung cancer, delivering information in real-time to support therapy selection, detection of emergent mutations and assessment of drug response.

Vishal Sikri, Vice President of Commercial Operations at Sysmex Inostics,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member